VBI Vaccines: COVID-19 Narrative Boosts Hepatitis B Vaccine Prospects [Seeking Alpha]
VBI Vaccines, Inc. - Ordinary Shares (VBIV)
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
vbivaccines.com/investors
Company Research
Source: Seeking Alpha
Investment ThesisOnce a micro-cap beset by liquidity constraints, VBI Vaccines Inc. (VBIVThis year, both VBI-2601 and VBI-1901 are awaiting data readouts for their mid-stage trials, while the company's prophylactic hepatitis B vaccine, Sci-B-Vac, expects the regulatory approvals in the U.S. and Europe. Assuming even a small share of the hepatitis B vaccine market, our 2021 revenue projections with the current forward price to sales multiple highlight an undervalued stock. Given the risks of the experimental vaccine developer, the upside looks modest, but VBI is a 'Buy' for us as its COVID-19 vaccine program drives the stock's near-term momentum.Source:Company WebsiteCOVID-19 Vaccine Program Sparks a RallyAfter failing to meet the minimum bid price requirement, VBI was on theverge of delistingNBIbroke the newscoronavirus agentsIndex of CNBCtests and treatmentsKoyfinNRC, Canada's largest federal research and development organization, is reputed for its expertise in vaccine development.
Show less
Read more
Impact Snapshot
Event Time:
VBIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VBIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VBIV alerts
High impacting VBI Vaccines, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VBIV
News
- VBI Vaccines Inc. (NASDAQ: VBIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VBI Vaccines Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Reports Full Year 2023 Financial ResultsBusiness Wire
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness Wire
VBIV
Earnings
- 11/14/23 - Miss
VBIV
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 10-K
- 4/16/24 - Form 8-K
- VBIV's page on the SEC website